DUOGLOBE is a multinational observational study (including US sites) of LCIG naïve patients treated during routine clinical practice with 3-years follow-up planned (NCT02611713). This is the first multinational LCIG study using the Unified Dyskinesia Rating Scale (UDysRS). Other assessments included the UPDRS Part IV, “Off” time, Non-Motor Symptoms Scale (NMSS), QoL (8-item PD questionnaire [PDQ-8]), caregiver burden (MCSI), and Serious Adverse Events (SAEs). Interim outcomes from baseline to month (M) 24 are presented.

In this interim analysis, 196 patients were included (62% male, 78% ≥65 years old; 51% ≥10 years’ PD duration. Median daily duration of LCIG infusion was 16.0 h/d LCIG through M24, with up to 9% of patients on 24h LCIG infusion. Significant improvements (mean change from baseline to M24) were observed in “Off” time (-3.6 h/d) and NMSS total scores (-27.0). LCIG treatment significantly improved dyskinesia symptoms and signs assessed by the UDysRS and UPDRS Part IV items 33 and 34 through M18. QoL and caregiver burden were improved through M18. Overall, 41% of patients experienced SAEs; 31% (n=60) discontinued participation in DUOGLOBE with 13 patients continuing LCIG outside the study.  

This interim analysis shows sustained improvements of dyskinesia symptoms and signs, measured using the UDysRS, with LCIG in routine clinical practice and supports real-world effectiveness of LCIG on “Off” time, NMS, QoL, and caregiver burden in aPD patients. Safety was consistent with the established LCIG profile.